Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136786 · ClinicalTrials.gov registry record · Phase 1
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
A Phase 1 study of Tobacco Use Disorder, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00136786 is a Phase 1 study of Tobacco Use Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 25 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00136786, a Phase 1 study of Tobacco Use Disorder, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
One of nicotine's effects on the body is at the level of the NMDA receptors in the brain. Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment of nicotine addiction. The purpose of this study is to evaluate the effectiveness of memantine using a laboratory model of smoking relapse in nicotine dependent volunteers. Investigators will compare the effects of memantine with bupropion, medication currently used to facilitate smoking cessation.
Conditions Studied
Interventions
- DRUG Memantine
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136786
The ClinicalTrials.gov registry entry for NCT00136786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (90% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.
NCT00136786 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00136786 about?
NCT00136786 is a clinical study titled "Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3". One of nicotine's effects on the body is at the level of the NMDA receptors in the brain. Memantine is a drug that also affects NMDA receptors, making it a candidate for the treatment of nicotine addiction. The purpose of this study is to evaluate the effectiveness of memantine using a laboratory mo...
What is the current status of trial NCT00136786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-12. Estimated completion is 2009-05.
What conditions does trial NCT00136786 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00136786?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT00136786?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136786 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Cannabidiol for Tobacco Cessation
RECRUITING · Phase 1
-
Persistence-Targeted Smoking Cessation
COMPLETED · Phase 1
-
Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
COMPLETED · Phase 1
-
Lorcaserin for Preventing Weight Gain Among Smokers
COMPLETED · Phase 1
-
Brain Imaging in Tobacco Smokers During a Quit Attempt
COMPLETED · Phase 1
-
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.